A new antibody treatment for acromegaly
A First-in-Class Therapeutic Antibody for Treatment of Acromegaly
This study is testing a new treatment for acromegaly that uses a special antibody to help control growth hormone levels, aiming to provide better long-term health for people with this condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Elixera, INC. NIH-funded |
| Lab location | 1 site (Redwood City, United States) |
| Project ID | NIH-11008939 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapeutic antibody aimed at treating acromegaly, a rare endocrine disorder caused by excess growth hormone due to non-cancerous pituitary tumors. The project aims to provide a long-term solution for hormone control, which is currently inadequately addressed by existing therapies. By blocking the activity of growth hormone, this treatment could significantly improve health outcomes for patients suffering from this condition. The research will involve clinical testing to evaluate the effectiveness and safety of this new therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acromegaly who have not achieved adequate hormone control with existing treatments.
Not a fit: Patients who have not been diagnosed with acromegaly or those whose condition is adequately managed with current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with acromegaly, improving their quality of life and potentially extending their life expectancy.
How similar studies have performed: Other research has shown promise in developing antibody therapies for endocrine disorders, indicating potential success for this novel approach.
Where this research is happening
Redwood City, United States
- Elixera, INC. — Redwood City, United States (Active)
Researchers
- Principal investigator: Zanghi, Adiba — Elixera, INC.
- Study coordinator: Zanghi, Adiba
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.